chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Apparently, child experienced fever to 102F-103F later in the day, post vax, and was crying inconsolably and also had vomiting and diarrhea with symptoms. All occurred within 6 hours after receiving immunizations. Pt taken to local ER and admitted due to high white count (23,800) and for rule out of sepsis. Dx'd with possible viral syndrome; possible reaction to immunizations.
Pt recv vax on 10/12/98; on same day pt exp inconsolable crying & vax site rx of erythema, swelling & warmth
Pt. C/o dizzyness and weakness about 5-10 minutes after receiving her vaccine while seated in the observation area. Her husband and I walked her over to the cot and medical treatment area. Her pulse felt thready and weak while walking and her gait was unsteady. As soon as she sat, then lay on the cot she lost consciousness and did not respond to verbal or noxious stimuli over the next few minutes. I gave her one dose of an epi-pen into her left mid outer thigh but she still did not regain consciousness so we called a "Rapid Response code" for transport to the E.R. for further treatment and stabilization.
both eyes swollen/ one eye was swollen shut; both eyes watery; Vision is blurry; Eyes were itchy and painful; Eyes got very puffy; Minimal discharge; both eyes itching/Eyes were itchy and painful; both eyes red/Eyes got very puffy and very red; This is a spontaneous report from a contactable consumer. This consumer reported for 2 patients. This is the first of 2 reports.   A 52-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiry date unknown), via an unspecified route of administration on the left arm at the age of 52 years, on 07Jan2021 15:00 at a SINGLE DOSE for covid-19 immunisation. Medical history included ongoing breast cancer stage ii , mastectomy from Jun2018 to an unknown date. Concomitant medication included anastrozole (ANASTROZOLE), escitalopram oxalate (LEXAPRO) and atenolol (ATENOLOL). The patient previously took taxol and experienced drug hypersensitivity. The patient stated that this past Sunday (24Jan2021) that her daughter woke up with both eyes swollen, red, watery and itching. It was stated that they took her to the clinic and was told that this was the second one that they had seen like this. It was also stated that they gave her a prescription for eye drops. It was stated that she woke up this morning and one eye was swollen shut and wanted to know what to do or the course of action. It was stated that she was supposed to get her second shot Thursday and wanted to know if she should get her second dose or not. It was also stated that her eyes were swollen and red which were better yesterday and today are worst than they have ever been. It was stated that the left eye is more swollen than the right. It was also stated that she soaked tea bags and put them on her eyes Sunday and stated that she does not know the name of the prescription eye drops. On 17Jan2021, it was reported that the patient's eyes got very puffy and very red. Her eyes were itchy and painful with minimal discharge. Her vision was also blurry. The patient underwent lab tests and procedures which included sars-cov-2 test: negative on 12Jan2021, sars-cov-2 test: negative on 19Jan2021 and sars-cov-2 test: negative on 25Jan2021. Therapeutic measures (Eye drops; Prednisone; Polymixin)  were taken as a result of both eyes swollen/ one eye was swollen shut (eye swelling), both eyes red/eyes got very puffy and very red (ocular hyperaemia), both eyes watery (lacrimation increased), both eyes itching/eyes were itchy and painful (eye pruritus), vision is blurry (vision blurred) , eyes were itchy and painful (eye pain), eyes got very puffy (periorbital swelling) and minimal discharge (eye discharge). The outcome of the events was recovering.  Information on the lot/batch number has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021106157 similar report from same reporter
Numbness started in Right big toe. Numbness spread to other toes and into hands and right side of face. Felt like extremities were asleep. Most numbness has went away, but some numbness still exists in the right big toe.
The evening of receiving the vaccine, my heart starting racing. My blood pressure shot up to 150 over 95 and a blood vessel in my eye burst. The next morning I had a headache and my blood pressure remained elevated all day. I felt dizzy.  For the following 6 days, my heart would randomly race and I felt odd- just not myself. Blood pressure did go back to normal on 2/26/21.
Inappropriate age at vaccine administration; Infanrix was given to an adult patient instead of Boostrix; This case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 52-year-old female patient who received DTPa (Infanrix) (batch number 7ec55, expiry date unknown) for prophylaxis.   Co-suspect products included dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 20th August 2021, the patient received Infanrix and Infanrix Pre-Filled Syringe Device. On 20th August 2021, unknown after receiving Infanrix and Infanrix Pre-Filled Syringe Device, the patient experienced wrong vaccine administered. On an unknown date, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: Medical Assistant reported that a dose of Infanrix was given to an adult patient instead of Boostrix, which led to wrong vaccine administered and inappropriate age at vaccine administration. The reporter consented to follow up via email.
This spontaneous report as received from a nurse refers to a patient of unknown age and demographics. The patient's concurrent conditions, medical history, drug reactions/allergies and concomitant therapy were not reported. On 14-NOV-2018 the patient inadvertently vaccinated with expired dose of VAQTA 50/1.0 U/ml (lot # N023953, expiry date: 05-NOV-2018) (dose and frequency were not reported) intramuscularly for prophylaxis. No adverse effects were reported. No product quality complaint was involved.
slight nausea; Fever; arm soreness; This is a spontaneous report from a non-contactable consumer (patient). A 36-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Arm Left on 13Mar2021 13:15 (lot number and expiry date: unknown) at the age of 36-years-old, as dose 1, single for Covid-19 immunisation. Medical history included known allergies to sulfa. Concomitant medications included ganoderma lucidum (REISHI MUSHROOM); astragalus mongholicus (ASTRAGALUS); sambucus nigra fruit (ELDERBERRY [SAMBUCUS NIGRA FRUIT]); and clarithromycin (CLARITIN) all taken for unspecified indications, start and stop dates were not reported. The vaccine was administered in a pharmacy or drug store. The patient did not receive other vaccines in four weeks. The patient was not diagnosed with Covid-19 before vaccination. On 13Mar2021, at 22:00, the patient experienced fever, arm soreness, and slight nausea. The patient did not receive treatment for the events. Outcome of the events was recovering. The patient has not been tested for Covid-19 after vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information expected.
loss of appetite; loss of taste,; loss of energy; so dizzy; couldn't stand; body aches; This spontaneous case was reported by a consumer and describes the occurrence of DECREASED APPETITE (loss of appetite), AGEUSIA (loss of taste,), ASTHENIA (loss of energy), DIZZINESS (so dizzy) and DYSSTASIA (couldn't stand) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DECREASED APPETITE (loss of appetite), AGEUSIA (loss of taste,), ASTHENIA (loss of energy), DIZZINESS (so dizzy), DYSSTASIA (couldn't stand) and MYALGIA (body aches). At the time of the report, DECREASED APPETITE (loss of appetite), AGEUSIA (loss of taste,), ASTHENIA (loss of energy), DIZZINESS (so dizzy), DYSSTASIA (couldn't stand) and MYALGIA (body aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported.  The treatment information was unknown.   Reporter did not allow further contact
This case was reported in a literature article and described the occurrence of hepatitis B in a 9-month-old female subject who was vaccinated with Hepatitis B vaccine (manufacturer unspecified). Subject's mother was HBV mono-infected and positive for hepatitis B surface antigen (HBsAg) with HBV DNA levels greater or equal to 6 log copies/mL. She was negative for hepatitis C antibody and HIV infection. Subject's mother was treated as part of a study to reduce perinatal hepatitis B transmission with tenofovir disoproxil fumarate (TDF) 300 mg orally for only 17 days due to non-compliance with prenatal care. She was lost to follow-up until 35 weeks gestation, where at that time TDF was started. She delivered between 2009 and 2012 at 37 weeks and 5 days gestation via spontaneous vaginal delivery and breast-fed during her hospital stay. Subject's birth weight was 3,419 kg and Apgar scores of 8 at 1 and 9 at 5 minutes. On an unspecified date, within 12 h of birth, the subject received unspecified dose of Hepatitis B vaccine (unknown route, injection site and batch number) and hepatitis B immunoglobulin (HBIG). At the age of 9 or 12 months, between 9 and 12 months after vaccination with Hepatitis B vaccine and HBIG, the subject was tested positive for hepatitis B surface antigen due to vertical infection transmission. The subject was referred to a pediatric gastroenterologist for management. At the time of reporting the outcome of the event was unspecified. Author's conclusion: this is the second published case series to date on the use of TDF prophylaxis in HBV mono-infected, highly viremic mothers. This series suggests that the use of TDF in the third trimester reduces maternal HBV DNA levels and is well tolerated by pregnant women. Initiation of TDF in the third trimester in highly viremic women to reduce vertical transmission should be considered. Follow-up received on 25 June 2014: This case was upgraded to serious due to Hepatitis B infection. The author assumed that the subject completed the vaccination series but he had no access to the records. The subject was not symptomatic when the gastroenterologist saw him 3 months after the Hepatitis B diagnosis.
Pt was given a Covid vaccine for children 12 and over not the vaccine for his age group.
The morning following vaccinations, pts arm was red, warm and swollen. She began itching her hands, which were also reddened. By 1pm that day, urticaria developed on hands, vaccination site and neck. Was seen by MD who prescribed Benadryl 25mg q6 prn. A dose was given in the clinic and another at 8pm after patient's feet began to itch. No further doses given and by 12/2/04, patient has recovered.
Developed markedly red, indurated, swollen and painful left upper arm (elbow to shoulder) with fever, approx. 18 hours, post vax. Reaction subsided very slowly over approx. 8 days time.
Patient was given an overdiluted second dose of Covid vaccine Pfizer. She did not repeat dose as referenced by Pfizer. The vaccine vial was diluted twice. Patient has not reported side effects to the pharmacy.
Suspected COVID-19; SUSPECTED COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 75-year-old male patient received BNT162b2 (BNT162B2), on 25Jan2021 as dose 1, single (Lot number: el9262), in left arm, on 25Feb2021 as dose 2, single (Lot number: el9266), in left arm, on 26Aug2021 as dose 3 (booster), single (Lot number: fc3181), in left arm and on 31Mar2022 at 11:30 as dose 4 (booster), single (Lot number: fk9895) at the age of 74 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Mastocytosis emphysema" (unspecified if ongoing), notes: Mastocytosis emphysema; "Mastocytosis emphysema" (unspecified if ongoing), notes: Mastocytosis emphysema. The patient's concomitant medications were not reported. The following information was reported: SUSPECTED COVID-19 (medically significant) with onset 2022, outcome "unknown"; DRUG INEFFECTIVE (medically significant) with onset 2022, outcome "unknown", described as "Suspected COVID-19". Therapeutic measures were taken as a result of drug ineffective, suspected covid-19.  No follow-up attempts are possible. No further information is expected.
Patient under the age of 65 was mistakenly administered Fluad.  Patient monitored in pharmacy and via follow up phone call.  No adverse effect reported.
1135 RNs responded to vehicle 2 to c/o dizziness, numbness in hands, swelling nasal passages. Pt alert, oriented, denies SOB. Benadryl 25mg PO  ADMINISTERED PER 50 Driver moved car to front of lot. Pt reported further dizziness, headache, tongue becoming thick. 1145 RN  contacted Dr. instructions to give another 25mg Benadryl PO
Information has been received from a health professional concerning a 15 month old female, with no medical history, who on 5/18/2005, at 3:30pm, was vaccianted with a subcutaneous first dose in the upper right deltoid of varicella virus vaccine live (lot 649481/0764P). Concomitant vaccines administered on the same day included a first subcutaneous dose in the upper left posterior arm of measles virus vaccine live  (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3) (lot 647113/0346P) and a first intramuscular dose in the upper left vastus of Pneumococcal 4 6B 9V 14 18C 19F 23F conj vaccine (CRM197) (PREVNAR) (lot A65652K). At the time of vaccination it was noted that the patient was well and fever free, the patient had no problems after last shot, the patient has never had a convulsion, there were no children in the home who were no immunized, the patient had no problems with her immune system, no one around the child was taking cortisone or prednisone, the patient had no received blood products within the past year, no one around the patient had cancer, leukemia, AIDS virus, or lymphoma, the patient was not allergic to eggs, neither the patient or anyone in the family was allergic to neomycin, streptomycin, gelatin, or bakers yeast, and that the patient has no allergies. In approximately May 2005, the patient experienced break through chickenpox, described as mild with less than 50 lesions. It was reported that the patient was recovering. Unspecified medical attention was sought. No product quality complaint was involved. Follow up information from a health professional indicated that the patients mother called on 6/1/2005 and said that her child has had two rashes since 5/18/2005. One was 2-3 days after the immunizations with a fever, that was no measured by a thermometer. It was reported that the patient now has pinpoint red dots on her back and face with no fever. It was noted that it was recommended to the mother that the child had varicella, and to consider the rash contagious until the lesions crusted and healed. The reporter noted that child had possible vaccine acquired varicella disease. Subsequently, the patient recovered. The patients sibling experienced break through chickenpox following vaccination with varicella virus vaccine live (WAES0506USA01918). Additional information is not expected.
High fever, laying around. Fee days was acting a little different. Before vaccination was responding to name more.
Information has been received from a 49 year old male a ph. D. with an allergy to clindamycin and penicillin and asthma who on 10-OCT-2008 was vaccinated IM in the upper deltoid with PNEUMOVAX 23 (lot # not reported). Concomitant therapy included ADVAIR and pravastatin Na. The ph. D. reported he experienced some adverse effects after getting PNEUMOVAX 23. Around the weekend of 10-OCT-2008 the patient had swelling of the right arm, warmth, soreness and flu-like symptoms without fever. He was seen on 13-OCT-2008 because he was still having problems with arm. He was diagnosed with tendonitis and was put in a sling. On 17-OCT-2008 the pain got worse and he took MOTRIN, aspirin, or VICODIN. On Monday 20-OCT-2008 the patient could move his arm and the arm symptom was downgraded to a tennis elbow. The patient was recovering by the time of this report. Follow up information was received from the ph. D. who reported that he has not been able to play hockey for 2 months now (disabling) because his elbow still hurts. He had an MRI on his elbow which showed inflammation. Additional information has been requested.
SORE ARM; This spontaneous report received from a patient concerned a 51 year old adult male. The patient's height, and weight were not reported. The patient's concurrent conditions included: alcohol use (occasional, 1 per month), and non-smoker, and other pre-existing medical conditions included: The patient had no known allergies. The patient had no history of drug abuse or illicit drug use. Diagnostic data of the patient was not available. The patient previously received covid-19 vaccine ad26.cov2.s (unspecified manufacturer) (Dose number in series 1) (suspension for injection, route of administration, and batch number were not reported, expiry: unknown) dose was not reported, 1 total was administered on an unspecified date for prophylactic vaccination. No adverse events were reported following vaccination with covid-19 vaccine ad26.cov2.s (dose number in series 1).  The patient additionally received covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin, and batch number were not reported, expiry: unknown) dose was not reported, 1 total was administered on an unspecified date in OCT-2021 for prophylactic vaccination. The batch number was not reported and has been requested. Age at time of vaccination 51 years old. No concomitant medications were reported.  On an unspecified date in 2021, next day of vaccination, the patients arm was sore and was noticeably sore, especially with movement, for just over a month in duration. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from sore arm on an unspecified date in 2021 after just over a month duration. This report was non-serious. This case, involving the same patient is linked to 20210407672.
Moderate headache; fatigue; This is a spontaneous report from a contactable consumer. A 46-year-old male patient received (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 1st dose, single for covid-19 immunisation. Medical history included heart attack (4 years ago). The patient's concomitant medications were not reported. On an unspecified date, the patient experienced moderate headache and fatigue. Event took place after use of product. The outcome of the events was unknown.  No follow up attempts are possible. Information about lot/ batch number cannot be obtained.
Hospitalization for altered mental status, UTI and right-sided pneumonia on dates 5/1/2023- 5/10/2023. Treated with dexamethasone,  Remdesivir, vitamin C 1,000 mg PO daily, vitamin D 25 mcg PO daily, zinc 50 mg PO daily.
red rash bilateral forearms and chest. IM Benadryl 25mg right deltoid @ 1305
1:00 PM (07-01-2019) Injection site pain. Started to feel slightly dizzy, slightly weak, tired. These slowly increased as time passed. 12:00 AM (next day, 07-02-2019) Woke up with slightly above 100 degree fever, headache, elevated pulse rate (but usual, for me, blood pressure, which is slightly elevated) and generally not feeling well. Took 1,000 mg acetaminophen. 2:30 AM (07-02-2019) Feeling a little better, probably from acetaminophen, but cannot sleep because still not feeling well. So I researched side effects of Shingrix, found this website and decided to submit a report.
11x 6 cm area of erythema with warmth and swelling on right arm at site of vaccination.
Patient is a 22 y.o. male with PMH of obesity who presented to ED on 5/22 with c/o chest pain 3 days after receiving his second dose of Pfizer COVID-19 vaccine. Trop elevated to 12.7 and ECG with diffuse ST segment elevation consistent with pericarditis. He had an episode of NSVT. Trop peak 29. Patient was started on ASA + colchicine and metoprolol. TTE revealed LVEF 49% with multiple segmental abnormalities. Due to concern for worsening arrhythmia and possible need for myocardial biopsy patient was transferred to BMMC on 5/23.    Cardiology was consulted and cardiac MRI was performed. No further arrhythmias noted on telemetry monitoring. Cardiac MRI revealed LVEF 57% RVEF 53%, no vasodilator induced perfusion defect, delayed enhancement MRI is abnormal, epicardial enhancement of distal anterior and anterolateral walls with small pericardial effusion, consistent with perimyocarditis. Patient chest pain resolved and he denied other associated symptoms.Ttroponin level down to 5, VSS. Medically stable for discharge with no strenuous activities until inflammatory biomarkers normalize and close f/u with cardiology in 1 week.    New medications: - ASA 650mg TID for 7 days followed by ASA 325mg daily - Colchicine 0.6mg BID for at least 3 months - Metoprolol succinate 25mg daily    Follow up with cardiology clinic in 1 week with CRP, ESR, and troponin
This spontaneous report was received from a licensed practical nurse (L.P.N.) regarding an unknown number of patients of unknown age and unknown gender. No medical history and concurrent conditions were reported. On 19-NOV-2015, 22-NOV-2015, 25-NOV-2015 and 01-DEC-2015, these patients were vaccinated with improperly stored RECOMBIVAX HB (dose number, anatomical location frequency and route unknown) with a lot number # K009953 and expiry date 03-APR-2016. Concomitant medications of the patient were unknown. No other adverse events were reported. No product quality complaint was reported. This is one of the several reports from the same reporter. Additional information has been requested.
no local rxn;both arms aching/hurting (six pillows to sleep on) per nurse - pt saw pvt MD;K+ low placed on K+ supplement by MD;pt also had URI & on ATB;
On day of vaccine went to Urgent Care with symptoms of puffy tongue, tight chest. Next day numbness in arms and legs including memory problems. She was diagnosed with polyneuropathy in both legs.
Bruise on left arm; This is a spontaneous report from a contactable consumer (patient). A 36-year-old female patient received the first dose of bnt162b2 (BNT162B2, lot number and expiry date were not reported), via an unspecified route of administration on 25Jan2021 08:15 PM at a single dose on the left arm for COVID-19 immunization. The most recent COVID-19 vaccine was administered at School or Student Health Clinic. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not pregnant at the time of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Medical history was none. The patient has no known allergies to medications, food, or other products. Concomitant medications included iron, birth control, prenatal vitamins. On 26Jan2021, the patient experienced bruise on left arm. No treatment was received for the events. Outcome of the event was not recovered. The reporter assessed the events as non-serious. Since the vaccination, the patient not been tested for COVID-19.  Information on the lot/batch number has been requested.